Trending Now
How Dyadic International Inc (NASDAQ:DYAI) Fits into the Vaccine 2.0 Gold...
Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Kintara Therapeutics Inc. (NASDAQ: KTRA) Announce Multi-Year Grant for to Dr....
Kintara Therapeutics Inc. (NASDAQ: KTRA) has announced a multi-year research grant from Luxembourg National Research Fund (FNR) and Cancer Foundation Luxembourg to Dr. Anna...
MAKE IT MODERN
LATEST REVIEWS
Stocks for the Pandemic Long Haul (FLGT, ALST, HOLX)
Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be...
MAKE IT MODERN
PERFORMANCE TRAINING
CytoDyn (OTCMKTS:CYDY) Investor Update Unveils Coming Uplisting and Potential Interim Readout Followed by a...
Yesterday CytoDyn Inc. (OTCMKTS) delivered a gripping investor update after hours clearly projecting a bright path forward that...
US FDA Places Mind Medicine Inc.’s (NASDAQ: MNMD) IND Supporting Phase 2 LSD Study...
Mind Medicine Inc. (NASDAQ: MNMD) has announced that the US FDA has placed a clinical hold on its IND application that intends to support...
Atossa Therapeutics Inc (NASDAQ:ATOS) Reports Tolerability And Safety Of AT-301 In Clinical Trial Phase...
Atossa Therapeutics Inc (NASDAQ:ATOS) reported positive results from the Phase 1 clinical trial of its innovative drug candidate AT-301. Currently, no FDA-approved treatments are...
Allogene Therapeutics Inc. (NASDAQ: ALLO) Releases Posotve Data Form {Phase 1 UNIVERSAL ALLO-32 Study...
Allogene Therapeutics Inc. (NASDAQ: ALLO) has announced positive updated findings of Phase 1 UNIVERSAL study of single-dose ALLO-32 in r/r multiple myeloma.
Allogene presents ALLO-32...
Halozyme Therapeutics Inc. (NASDAQ:HALO) Announce That The EMA Has Approved Jannsen’s Subcutaneous DARLEX Formulation
Halozyme Therapeutics Inc. (NASDAQ:HALO) has announced that Janssen-Cilag International has received marketing approval from the European Commission for DARZALEX (daratumumab) which is a subcutaneous...
MAKE IT MODERN
